FDA Panel Supports Expanded Indications For Medtronic CRT-D Devices
This article was originally published in The Gray Sheet
Executive Summary
Despite data concerns, FDA’s Circulatory System Devices advisory panel favors expanding the indications for Medtronic cardiac resynchronization therapy-defibrillator devices to allow treatment of heart failure patients with milder symptoms.